Protagenic Therapeutics, Inc.\new
AI Executive Summary
AI-powered analysis of 10-Q filing content
Protagenic Therapeutics shows severe financial distress with a stockholders' deficit of $2.4M and current liabilities of $6.8M against only $2.2M cash. Despite a recent cash infusion increasing from $14K to $2.2M, operating losses have quadrupled to $4.4M over nine months with minimal revenue generation. The company faces immediate liquidity concerns and potential insolvency.
Red Flags Detected (7)
Stockholders' deficit of $2.4M indicating negative book value
Current liabilities ($6.8M) exceed total assets ($4.4M) by $2.4M
Operating losses increased 306% to $4.4M in nine months vs $1.1M prior year
4 more red flags detected
Key Takeaways
Company is technically insolvent with liabilities exceeding assets
Recent capital infusion provided temporary liquidity but burn rate unsustainable
2 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.